Transmedics Group Inc
NASDAQ:TMDX

Watchlist Manager
Transmedics Group Inc Logo
Transmedics Group Inc
NASDAQ:TMDX
Watchlist
Price: 136.51 USD -1.53% Market Closed
Market Cap: 4.7B USD

Transmedics Group Inc
Investor Relations

TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists.

Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Oct 29, 2025
AI Summary
Q3 2025

Revenue Growth: TransMedics reported Q3 2025 revenue of $143.8 million, up 32.2% year-over-year, with growth across all organ segments.

Margin Expansion: Gross margin was 59%, up nearly 290 basis points YoY; operating margin reached 16% versus 4% last year.

Guidance Raised: Full-year 2025 revenue guidance was increased to $595–605 million, representing approximately 36% growth at the midpoint over 2024.

Strong Cash Position: Cash balance grew by $65.6 million in Q3 to $466.2 million, driven by improved billing and collections.

International Expansion: Plans to launch the first international NOP program in Italy in H1 2026, with further European and global expansion envisioned.

Clinical Programs: Next-gen heart and lung trials to begin enrolling in Q4 2025 with revenue contribution expected to start this year, and full trial ramp-up in early 2026.

Fleet Efficiency: Achieved goal of 22 owned aircraft and are piloting double shifting to drive logistics efficiency.

Long-Term Targets: Confident in reaching 10,000 transplants by 2028, with further upside from heart, lung, and kidney programs.

Key Financials
Revenue
$143.8 million
Gross Margin
59%
Operating Profit
$23.3 million
Operating Margin
16%
Net Income
$24 million
Cash Balance
$466.2 million
Earnings Per Share
$0.71
Diluted Earnings Per Share
$0.66
U.S. Transplant Revenue
$139 million
Liver Segment Revenue
$108 million
Heart Segment Revenue
$27 million
Lung Segment Revenue
$4 million
OUS Revenue
$3.6 million
Product Revenue
$88 million
Service Revenue
$56 million
Transplant Logistics Service Revenue
$27.2 million
Total Operating Expenses
$61 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Nicholas Corcoran
Senior Vice President of Supply Chain & Operations
No Bio Available
Mr. Anil Ranganath
Senior VP, General Counsel & Corporate Secretary
No Bio Available
Ms. Miriam C. Provost Ph.D.
Vice President of Global Regulatory Affairs
No Bio Available

Contacts

Address
MASSACHUSETTS
Andover
200 Minuteman Road
Contacts
+19785520900.0